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Abstract
Background: Recently, the use of transcatheter aortic valve implantation (TAVI) in inter-
mediate-low risk patients has been evaluated in the PARTNER II randomized trial. However, 
in the last years, this therapy has been employed in this scenario with underreported results, 
as compared to surgical aortic valve replacement (SAVR).
Methods: We enrolled 362 consecutive patients with severe symptomatic aortic stenosis and 
intermediate-low surgical risk (logEuroSCORE < 20%), treated in our center with TAVI 
(103 patients) or single SAVR (259 patients) between 2009 and 2014. Patients were matched 
according to age, gender, logEuroSCORE, and use of bioprosthesis.
Results: Mean age of the patients was 73 ± 10.4 years, and 40.3% were women. Log-
EuroSCORE and Society Thoracic Surgeons score were 7.0 ± 4.4% and 4.2 ± 2.5%, re-
spectively, with mean left ventricular ejection fraction of 52 ± 9%. There were no differences 
regarding other comorbidities. The length-of-hospitalization was 11 ± 5 days after TAVI vs. 
17 ± 9 days after SAVR (p = 0.003). After matched comparison, no differences in terms of 
in-hospital mortality (5.7% after TAVI vs. 2.9% after SAVR, p = 0.687) and 1-year mortality 
(11.4% vs. 7.1%, p = 0.381) were found. The combined endpoint of stroke and mortality at 
1-year was also similar between both groups (15.7% in TAVI patients vs. 14.4% after SAVR, 
p = 0.136). Multivariate analysis determined that aortic regurgitation (AR) was an inde-
pendent predictor of mortality (OR = 3.623, 95% CI: 1.267–10.358, p = 0.016). Although 
the rate of AR was higher after TAVI, none of the patients treated with the newest generation 
devices (10.7%) presented more than a mild degree of AR.
Conclusions: TAVI is feasible and shows comparable results to surgery in terms of early, 
1-year mortality, as well as cerebrovascular events in patients with severe aortic stenosis 
and intermediate-low operative risk. Better transvalvular gradients, yet higher rates of AR 
were found, however, newer devices presented comparable rate of AR. (Cardiol J 2016; 23, 
5: 541–551)
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Introduction
Degenerative aortic stenosis (AS) is the most 
common valve disease in our environment, affect-
ing up to 7% of patients over 80 years of age [1]. For 
decades, the gold standard treatment was surgical 
aortic valve replacement (SAVR) in patients with 
acceptable surgical risk, but the development of 
transcatheter aortic valve implantation (TAVI) 
radically changed this scenario. Several rand-
omized and observational studies have reported 
superior survival rate of symptomatic high-risk AS 
patients, as opposed to medical treatment [2, 3], 
and comparable, or even superior results in lower 
risk subgroups with surgery [3–5].
As a matter of fact, the enthusiastic embrace 
of this new therapeutic approach has led to the use 
of TAVI in lower risk patients in the real-world 
practice. Although results from larger registries 
seemed good with both, TAVI and SAVR, these 
two therapeutic alternatives had not been com-
pared until recently through the NOTION [5] and 
PARTNER II studies [6], both with the former 
generation of TAVI devices, and the SAPIEN-3 
non-randomized sub-study [7]. It is noteworthy 
that currently, clinical practice guidelines do not 
recommend TAVI for lower risk patients. Although 
these new studies [5–8] will shed light upon the 
management of a great amount of patients with 
such a dilemma, the high cumulative experience 
from the past years offers valuable information that 
cannot be ignored when choosing the best thera-
peutic alternative for our patients [9–12].
Since the beginning of our TAVI program in 
2009, a heart-team based decision-making process 
has been used in our institution (Fig. 1), and pro-
spective record of events for both, TAVI and SAVR 
patients, has been performed as the best way to 
audit the results. The present study aims to report 
our one-center experience in the treatment of in-
termediate and low risk TAVI patients as compared 
to a matched population who underwent SAVR in 
the same period in our institution.
Methods
Study population
A total of 362 patients with isolated sympto-
matic severe AS and intermediate-low risk who 
underwent TAVI or isolated SAVR between 2009 
and 2014 in our institution were included in this 
study. The study was approved by the local bioethi-
cal committee and all patients gave their informed 
consent. The index population from our region 
included up to one million inhabitants with an 
average of 500 extra-corporeal surgeries per year 
and about 50 TAVI procedures per year. Patients’ 
data were prospectively recorded by investiga-
tors from baseline and up to 2 years of follow-up 
(J.C.; J.T.; I.J.A.S.; I.M.; and C.C. participated in 
data collection of TAVI patients; S.D.S. and M.B. 
collected the data for SAVR group). Patients were 
considered to belong to intermediate and low 
surgical risk on the basis of the clinical assess-
ment by our Heart Team considering an estimated 
Logistic EuroSCORE below 20%, as it was in the 
high risk cohort sub-analysis of PARTNER trial. 
Both, high risk patients according to the same 
score and those deemed unoperable by the Heart 
Team irrespective of their estimated score, were 
excluded from our study population. Neither pa-
tients with severe mitral valve disease, nor those 
with severe coronary disease who were considered 
candidates for multivalvular and/or revasculariza-
tion surgery were included. Decision of the Heart 
Team to operate the patient or not was based on 
the guidelines [13, 14] considering not only the 
risk score but also the age, comorbidities, patient’s 
preference, and frailty (Fig. 1). The last feature 
was assessed with Charlson index score, serum 
albumin (systematically recorded) and, in selected 
patients, 5-m walk test and 6-min walk distance 
tests (10% of the population, 20.6% of those aged 
over 80 years old). The final decision on frailty was 
based on all these factors together with eyeball 
test assessment. Other variables, such as aortic 
root disease or porcelain aorta were also taken into 
account after careful evaluation through computed 
tomography in borderline cases, in order to plan 
the procedure. If excessive risk was estimated 
for aorta clamping, this fact tipped the balance in 
favor of TAVI.
In-hospital and follow-up outcomes
Follow-up was performed through clini-
cal visits or telephone contact at 30 days, 6 and 
12 months, and annually thereafter. The follow-up was 
available in 100% of the study population. SAVR 
patients were followed by clinical visit, available 
for all patients at 1-month follow-up, and telephone 
contact. At 1-year follow-up clinical reports were 
available for 82.2% of patients (either from our 
institution or from local hospitals), and for the 
rest the follow-up variables were gathered through 
telephone contact. TAVI patients were followed 
in our institution at least for the first year and 
afterwards through telephone contact and clini-
cal report gathered from their local institutions. 
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Primary endpoints were in-hospital and 1-year 
mortality, stroke at 1-year, and the combined end-
point of mortality and stroke at 1-year follow-up. 
Assessment of cardiac mortality was performed 
following definitions from VARC-2 [15]. Second-
ary endpoints included the rate of pacemaker 
implantation, major bleeding (according to VARC-2 
criteria) [15], in-hospital stroke, and the rate of 
significant aortic regurgitation (AR ≥ 2) after the 
procedure. Cerebrovascular events were evalu-
ated by a neurologist. The diagnosis was assumed 
if there were compatible symptoms (worsening in 
the Modified Rankin Scale), or if compatible im-
ages of acute stroke were present in the cerebral 
computed tomography scan in oligosymptomatic 
patients. Aortic regurgitation was determined by 
Figure 1. Algorithm followed by our Heart Team for therapeutic decision in patients suffering from severe sympto-
matic aortic stenosis; BMI — body mass index; COPD — chronic obstructive pulmonary disease; CKD — chronic 
kidney disease; CT — computed tomography; STS — Society of Thoracic Surgeons; TAVI — transcatheter aortic 
valve intervention; TEE — transesophageal echocardiography; TTE — transthoracic echocardiography; *Know fac-
tors that increase the operative risk.
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transthoracic echocardiography and its gradation 
followed the recommendations of the European 
guidelines [16].
Statistical analysis
Continuous variables are expressed as mean 
(standard deviation) or median (25th–75th percentile) 
depending on variable distribution. Group com-
parisons were performed using Student’s t-test 
or the Wilcoxon test for continuous variables, and 
c2 test or Fisher’s exact test for categorical vari-
ables. The univariable normality assumptions were 
verified with the Shapiro-Wilk test. A propensity 
score matching analysis was performed to adjust 
for intergroup (SAVR vs. TAVI) differences in 
baseline characteristics caused by the selection 
bias inherent to the non-randomized nature of the 
study. By using a logistic regression analysis, the 
probability of being assigned to high vs. interme-
diate-low risk was calculated from baseline and 
procedural characteristics. Variables exhibiting 
a p-value < 0.10 in the univariate analysis were in-
cluded in the logistic regression analysis. Variables 
selected for matching, all of them prospectively 
collected, were age, logistic EuroSCORE, and 
use of bioprosthesis (all patients with mechanical 
prosthesis were excluded from this comparison). 
The reason for choosing these variables was the 
finding of significant differences between the two 
groups in the baseline analysis. In addition, inclu-
sion of gender in the matched model was decided 
upon, given the known impact of this variable in 
outcomes of valvular interventions [17, 18]. By 
using these co-variables, a propensity score was 
calculated for each patient, and patients of the two 
groups (SAVR vs. TAVI) were matched using a one-
to-one matching process. The maximum difference 
of propensity score for a match was established at 
10%. Comparable patient groups including a total of 
140 patients (SAVR group: 70 patients, TAVI group: 
70 patients) were identified for the analysis. A Cox 
multivariable analysis including all variables with 
p value < 0.05 in the univariable analysis was used 
to determine the predictive factors of cumulative 
late mortality. Late outcomes were also assessed 
by Kaplan-Meier estimates and compared using 
the log rank test for both, the global population 
and population after matching. Risk-strata sub-
analysis in patients with intermediate risk over 
and under 10% was also performed. The results 
were considered significant with p values < 0.05. 
Statistical analyses were performed with the sta-
tistical package SPSS, version 18.0 (SPSS, Inc.; 
Chicago, Illinois, USA).
Results
Main baseline characteristics of  
TAVI and SAVR patients
A total of 362 patients with intermediate-low 
surgical risk attributed to TAVI (103 patients, 
28.4%) or SAVR (259 patients, 71.6%) were in-
cluded in this research. Reasons that determined 
the preference of the Heart Team between these 
techniques were gathered and are schematically 
summarized in Table 1. Mean age of the entire 
intermediate-low risk study population was 73 ± 
± 10 years and 40.3% of patients were women, with 
a mean logistic EuroSCORE of 7.0 ± 4.4%, a mean 
Society of Thoracic Surgeons (STS) score of 4.2 ± 
± 2.5%, and left ventricular ejection fraction 
of 58 ± 9%. Other important characteristics have 
been compared between both strategies in Table 2.
To remark, among TAVI patients, 91 (88.3%) 
were treated with self-expandable system (83 
Corevalve and 8 Corevalve Evolute, Medtronic 
Inc., MN, USA) and 12 (11.6%) underwent balloon-
expandable prosthesis (9 Edwards-SAPIEN XT 
and 3 Edwards-SAPIEN-3, Edwards Lifesciences 
Inc., CA, USA). The approach was transfemoral in 
89.3% of them. In the SAVR group, the prosthesis 
was mechanical in 42.5% of patients (110 patients) 
and in 149 (57.5%), the chosen device was a bio-
prosthesis. Mean hospital stay was 15.6 ± 15.4 
days with a mean stay in the intensive care unit of 
3.5 ± 5.5 days (TAVI patients: 3.1 ± 4.7 vs. SAVR 
patients: 9 ± 10.1 days, p = 0.006).
Significant differences between both groups 
were found in terms of logistic EuroSCORE (TAVI 
Table 1. Main reasons to refuse conventional 
surgery among patients with intermediate to  
low surgical risk.
Global TAVI population N = 103
Cardiovascular comorbidities: 63 (61.2%)
Left ventricular severe dysfunction 36 (34.9%)
Moderate mitral regurgitation 20 (19.4%)
Porcelain aorta 4 (3.9%)*
Dilated ascending aorta 3 (2.9%)
Non-cardiovascular comorbidities: 32 (31.1%)
Respiratory disease 15 (14.6%)
Anatomical issues of the thorax 6 (5.8%)*
Liver disease 3 (2.9%)*
Other comorbidities 8 (7.7%)*
Patient’s preference 8 (7.7%)
*Potentially underestimated risk according to usual operative risk 
scores (S = 20.3%); TAVI — transcatheter aortic valve implantation
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10.8 ± 4.1% vs. SAVR 5.6 ± 3.6%; p = 0.001) 
and relevant comorbidities, such as chronic kid-
ney disease (CKD) (TAVI 13.6% vs. SAVR 5%; 
p = 0.005) and chronic obstructive pulmonary 
disease (COPD) (TAVI 28.2% vs. SAVR 16.6%; 
p = 0.013). Also, patients in the TAVI group were 
older with mean age of 81 ± 6.9 vs. 70 ± 9.9 years 
in the SAVR group, p = 0.001. In particular, among 
TAVI patients, 62% of them were above 80 years as 
compared to 9.3% in the SAVR cohort (p < 0.001). 
In order to reduce the impact of these baseline 
differences in the comparison of both techniques 
(TAVI and SAVR), a propensity score analysis was 
performed after a 1:1 matching process including 
the main baseline variables presenting the dif-
ferences. Moreover, gender was included in the 
matching process. Given that COPD and CKD are 
included in the logistic EuroSCORE, only the latter 
was selected for matching.
A total of 140 patients (70 TAVI patients and 70 
SAVR patients) underwent matched comparison. 
Baseline characteristics of the selected patients 
are summarized in Table 2.
In-hospital and follow-up outcomes
All patients were followed for at least 1 year. 
In-hospital and follow-up outcomes have been 
summarized in Table 3.
The global population did not present differ-
ences in terms of major bleeding (TAVI 11.7% vs. 
SAVR 15.4%; p = 0.353) or in-hospital stroke (TAVI 
1.9% vs. SAVR 5.4%; p = 0.119). On the contrary, 
the rates of permanent pacemaker implantation 
(20.4% vs. 6.6%; p < 0.001) and aortic regurgitation 
Table 2. Baseline characteristics according to the use of transcatheter aortic valve implantation (TAVI) 
or surgical aortic valve replacement (SAVR) in the global study population and 1:1 matched study 
population.
Variables Global data Matched data*
TAVI  
(n = 103)
SAVR  
(n = 259)
P TAVI  
(n = 70)
SAVR  
(n = 70)
P
Baseline characteristics
Age [years] 81 ± 6.9 70 ± 9.9 0.001 79 ± 7.7 78 ± 5.6 0.381
Gender (female) 41 (39.8%) 105 (40.5%) 0.898 34 (48.6%) 36 (51.4%) 0.136
LogEuroSCORE [%] 10.8 ± 4.1 5.6 ± 3.6 0.001 9.4 ± 3.8 9.3 ± 3.9 0.735
STS score [%] 5.3 ± 2.4 4.1 ± 2.6 0.001 4.6 ± 2.1 4.3 ± 2.4 0.326
Diabetes mellitus 34 (33%) 60 (23.2%) 0.054 26 (37.1%) 18 (25.7%) 0.185
Arterial hypertension 71 (68.9%) 165 (63.7%) 0.346 45 (64.3%) 51 (72.9%) 0.362
CKD 14 (13.6%) 13 (5%) 0.005 11 (15.7%) 6 (8.6%) 0.302
COPD 29 (28.2%) 43 (16.6%) 0.013 21 (30%) 11 (15.7%) 0.064
NYHA III–IV 56 (54.4%) 126 (48.6%) 0.326 37 (52.9%) 40 (57.1%) 0.749
Previous AF 16 (15.7%) 45 (17.4%) 0.700 9 (13%) 14 (20%) 0.405
Previous pacemaker 5 (4.9%) 5 (1.9%) 0.153 2 (2.9%) 1 (1.4%) 0.999
Previous LBBB 4 (3.9%) 8 (3.1%) 0.746 0 (0%) 2 (2.9%) 0.496
Baseline echocardiogram
Left ventricular ejection fraction [%] 59 ± 12.9 57.7 ± 3.6 0.126 58.2 ± 13.6 57.9 ± 4.5 0.159
Aortic regurgitation ≥ 2 29 (28.4%) 64 (24.7%) 0.493 20 (28.6%) 20 (28.6%) 0.999
Aortic valve area [cm2] 0.62 ± 0.15 0.64 ± 0.22 0.650 0.62 ± 0.16 0.67 ± 0.23 0.266
Maximum gradient [mm Hg] 80.2 ± 21.3 80.6 ± 25.8 0.897 79.4 ± 19.2 77.5 ± 29.6 0.869
Medium gradient [mm Hg] 51.3 ± 13.8 50.8 ± 17.9 0.819 50.2 ± 12.7 49.7 ± 19.9 0.921
Severe PHT [mm Hg] 11.7% 10 (3.9%) 0.005 7 (10%) 7 (10%) 0.999
*Matched for LogEuroSCORE, use of bioprosthesis, age, and gender. 
Data are expressed as absolute frequency and percentages for qualitative variables and as mean and standard deviation for quantitative vari-
ables. A comparison between groups was performed using Student’s t-test or U Mann-Whitney test depending on the distribution, and by 
Fisher exact test for categorical variables; AF — atrial fibrillation; CKD — chronic kidney disease (clearance with MDMR < 60 mL/min);  
COPD — chronic obstructive pulmonary disease; LBBB — left bundle branch block; NYHA — New York Heart Association; PHT — pulmonary 
hypertension; STS — Society of Thoracic Surgeons
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(AR ≥ 2) (TAVI 28.2% vs. SAVR 2.9%, p = 0.001) 
were higher after TAVI. Echocardiographic results 
demonstrated lower gradients and larger aortic 
valve area after TAVI with no differences in left 
ventricular ejection fraction.
Of note, in-hospital stay was shorter after 
TAVI (11 ± 5 days) than in SAVR patients (17 ± 
± 9 days, p = 0.003). However, in-hospital mor-
tality rate after TAVI (6.8%) was higher than 
after SAVR (3.5%), p = 0.168, reaching statistical 
significance at 1-year follow-up with 12.6% in the 
TAVI group and 4.6% after surgery (p = 0.007). 
In deeper detail, death was mainly of cardiac etiol-
ogy in 37% of the TAVI patients who died within 
the first year, as opposed to 80% of those treated 
surgically (p = 0.008).
After a matched comparison, differences in 
mortality diminished, leading to an in-hospital 
mortality rate of 5.7% after TAVI vs. 2.9% after 
SAVR (p = 0.687), and mortality at 1-year of 
11.4% and 7.1% after TAVI and SAVR, respectively 
(p = 0.381). The combined endpoint of stroke and 
mortality at 1-year was also similar between both 
groups, with 15.7% in TAVI patients and 14.4% 
after SAVR (p = 0.136).
Univariate analysis revealed that the use of 
TAVI and the presence of residual significant AR 
were the main determinants of cumulative mortal-
ity in the global population. However, multivariate 
analysis in the matched population indicated only 
AR as an independent predictor of mortality with 
odds ratio (OR) = 3.623 (95% confidence interval 
[CI] 1.267–10.358, p = 0.016). What is worth men-
tioning is that none of the patients treated with the 
newest generation devices presented more than 
a mild degree of AR. Apart from that, in the sub-
group with lower estimated surgical risk (logistic 
EuroSCORE < 10%), also AR ≥  2 resulted as 
an independent predictor of mortality at 1 year 
(OR = 3.66, 95% CI 1.92–14.56, p = 0.006). Survival 
Table 3. In-hospital and follow-up outcomes according to the use of transcatheter aortic valve  
implantation (TAVI) or surgical aortic valve replacement (SAVR) in the global study population and  
1:1 matched study population.
Variables Global data Matched data*
TAVI  
(n = 103)
SAVR  
(n = 259)
P TAVI  
(n = 70)
SAVR  
(n = 70)
P
Periprocedural outcomes
Transfemoral 92 (89.3%) – – 65 (92.8%) – –
Self-expandable 91 (88.4%) – – 68 (97.1%) – –
Biological prosthesis 103 (100%) 149 (57.5%) < 0.001 70 (100%) 70 (100%) 0.999
Left ventricular ejection fraction [%] 58.7 ± 11.5 56.7 ± 3.6 0.132 58.3 ± 12.1 58.4 ± 5.1 0.167
Aortic regurgitation ≥ 2 29 (28.2%) 8 (3.0%) 0.001 21 (30%) 2 (2.9%) 0.001
Aortic valve area [cm2] 1.48 ± 0.34 1.26 ± 0.15 0.001 1.47 ± 0.32 1.24 ± 0.16 0.001
Maximum gradient [mm Hg] 19.1 ± 14.9 30.7 ± 16.9 0.001 20.6 ± 16,9 30.8 ± 15.7 0.001
Medium gradient [mm Hg] 10.8 ± 10 17.9 ± 10.8 0.001 11.8 ± 11.1 18 ± 9.1 0.001
Major bleeding** 12 (11.7%) 40 (15.4%) 0.353 4 (5.7%) 8 (11.4%) 0.183
Permanent pacemaker 21 (20.4%) 17 (6.6%) < 0.001 12 (17.1%) 8 (11.4%) 0.334
In-hospital stroke 2 (1.9%) 14 (5.4%) 0.119 0 (0%) 3 (4.3%) 0.122
In-hospital mortality 7 (6.8%) 9 (3.5%) 0.168 4 (5.7%) 2 (2.9%) 0.687
Follow-up outcomes
Mortality (1 year) 13 (12.6%) 12 (4.6%) 0.007 8 (11.4%) 5 (7.1%) 0.381
Cardiovascular mortality (1 year)*** 5 (38%) 10 (83%) 0.008 4 (50%) 3 (60%) 0.999
Stroke (1 year) 3 (2.9%) 37 (14.3%) 0.021 3 (4.2%) 5 (7.1%) 0.392
Mortality/stroke (1 year) 16 (15.5%) 49 (18.9%) 0.678 11 (15.7%) 10 (14.4%) 0.136
*Matched for LogEuroSCORE, use of bioprosthesis, age, and gender
**Bleeding according to VARC-2 criteria including bleeding due to vascular complications.
***Mortality due to cardiovascular cause (% upon the global death) defined as death from cardiac causes, non-coronary vascular cause, 
periprocedural death, valvular causes, sudden death and death of unknown cause (VARC-2 criteria).
Data are expressed as absolute frequency and percentages for qualitative variables and as mean and standard deviation for quantitative  
variables. A comparison between groups was performed using Student’s t-test or U Mann-Whitney test depending on the distribution,  
and by Fisher exact test for categorical variables.
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curves according to the use of TAVI or SAVR have 
been depicted in Figure 2.
Discussion
Our results illustrate how challenging can be 
the selection of the best therapeutic strategy in 
patients with severe symptomatic AS and inter-
mediate-low surgical risk due to the wide range of 
concomitant factors that condition the actual risk. 
This may explain the variable results reported to 
date. In our experience, after initiation of the TAVI 
program, less than one third of patients estimated 
at lower risk were treated with percutaneous 
prosthesis. Main determinants were cardiovascular 
concomitant findings that underscore open surgery 
procedures, however, in a low and intriguing pro-
portion of candidates TAVI was selected due to 
patients’ preference.
Intermediate and low risk patients treated 
with TAVI appeared to be a less healthy popula-
tion, older, and with higher surgical estimated risk 
Figure 2. Survival curves according to the use of transcatheter aortic valve implantation (TAVI) or surgical aortic valve 
replacement (SAVR) in intermediate to low risk patients; Global population (A) and the matched population according 
to age, gender (B), logistic EuroSCORE, and use of bioprosthesis.
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than those deemed operable. Accordingly, they 
presented higher 1-year mortality. However, after 
reduction of these baseline differences through 
a propensity score matched process, a comparable 
mortality rate was found. On the contrary, the rate 
of significant AR after the intervention was higher 
after TAVI albeit, our initial experience with newer 
TAVI devices suggests that this issue may have 
been adequately addressed. The clear impact of AR 
on mortality in agreement with previous research, 
even in the group with lower surgical risk (logistic 
EuroSCORE < 10%), highlights the great potential 
impact of last-generation devices [19]. Indeed, our 
findings strongly suggest that we may be close to 
the surgery being overtaken by TAVI in terms of 
clinical outcomes in this lower risk group of pa-
tients, making device durability the last boundary.
Baseline profile of the study population
Intermediate and low risk patients selection 
is complex. Most scores in use in clinical practice 
have been developed to assess surgical risk but 
do not address the specific risks of percutaneous 
procedures [20]. Although STS score has been 
demonstrated to be more accurate in TAVI patients 
[21] and some specific tools have been developed to 
characterize the risk in this subset [22], we decided 
to use logistic EuroSCORE for risk stratification 
of the patients due to its prospective calculation in 
our sample and the fact that our Heart Team made 
decisions on the basis of this value, which confers 
to this score an exceptional validity in our scenario. 
In fact, it has been reported to be accurate in the 
past [23], although its cutoff value for high risk 
has not been clearly established and varies from 
15% to 20%.
The proportion of patients with severe AS and 
intermediate or low risk who are deemed for TAVI 
has not been reported in main registries, probably 
because of its wide variation among different re-
gions. In our experience, almost one third of lower 
risk patients were treated with TAVI. However, as 
described in Table 1, the actual risk may have been 
underestimated in one out of five patients due to 
several comorbidities affecting 20.6% of the popu-
lation. This is in agreement with the intermediate 
risk cohort of patients in PARTNER-II study, which 
in fact were considered to belong to the higher one 
fifth of patients with higher risk. On the other hand, 
7.7% of these patients were acceptable surgical 
candidates (mean logistic EuroSCORE of 4.7 ± 
± 3.9% and all of them aged over 80 years) but 
refused this therapy. Interestingly, all of them were 
alive at 1-year of follow-up with only two remark-
able events: the need for pacemaker implantation 
in 1 patient due to a complete atrioventricular 
block 4 days after the implantation, and a vascular 
(successful) intervention due to a failed femoral 
closure. In fact, age alone was probably one of the 
main factors that determined the use of TAVI in 
lower risk population despite the lack of evidence 
supporting this management [24]. Regarding this 
point, we conducted a sub-analysis between groups 
below and above 80 years old (Table 4), with no 
significant differences in the 1-year mortality rate 
between them.
Other important group of factors that deter-
mined the use of TAVI included disease of the aorta 
(dilation, or complex atheroma) and the presence 
of concomitant mitral regurgitation. In these two 
scenarios, the use of TAVI represents a partial 
solution to a complex problem with much higher 
risk if operated [25–27]. On the one hand, clamping 
a dilated and/or diseased aorta may damage this 
structure leading to the need of Bentall interven-
tion which increases the risk of comorbidities 
related to the intervention [28]. From another 
point of view, the medical management of moder-
ate mitral regurgitation during aortic surgery has 
been associated to worse outcomes [25], while in 
Table 4. In-hospital and follow-up outcomes according to therapeutic strategy (SAVR vs. TAVI) in  
different cohorts according to age (cutoff: 80 years old).
Variables £ 80 years old (275 patients) > 80 years old (87 patients)
TAVI  
(n = 40)
SAVR  
(n = 235)
P TAVI  
(n = 63)
SAVR  
(n = 24)
P
In-hospital mortality 2 (5%) 9 (3.8%) 0.665 5 (7.9%) 0 0.316
In-hospital stroke 2 (5%) 18 (7.7%) 0.748 3 (4.8%) 1 (4.2%) 0.999
Mortality (1 year) 4 (10%) 11 (4.7%) 0.247 9 (14.3%) 1 (4.2%) 0.272
Mortality/stroke (1 year) 6 (15%) 28 (11.9%) 0.604 12 (19%) 2 (8.3%) 0.332
SAVR — surgical aortic valve replacement; TAVI — transcatheter aortic valve implantation
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TAVI patients up to 60% may improve the degree 
of mitral regurgitation after the procedure [29, 
30]. Therefore, not only baseline characteristics 
but also procedural differences play a role in the 
estimation of outcomes with each technique. Re-
garding this point, several discussions may come 
about around alternative accesses for TAVI. In our 
series, 11 procedures were decided to be transapi-
cal, with longer rates of in-hospital stay (average 
of 17 days) and worse outcomes: 2 in-hospital 
deaths, 3 complete left bundle branch block, 1 in-
hospital re-intervention and 3 deaths in the first 
6 months. For this reason, alternative approaches 
such as transaxillary access have been adopted in 
our institution, with promising results.
Procedural features and in-hospital  
outcomes
Technical differences between TAVI and SAVR 
(transfemoral and with sedoanalgesia in about 90% 
of the TAVI patients and with general anesthesia, 
sternotomy, and aorta clamping in all SAVR) can 
explain a majority of the differences in acute out-
comes. Although at the beginning of TAVI proce-
dures there was great concern about the risk of 
stroke (over 5% at that time) [31], the reduction 
in the profile of the devices and the simplification 
of the procedure may explain the lower rates of 
this problem after TAVI than after SAVR in our 
series. This is in agreement with recent research 
suggesting a higher rate of subclinical stroke after 
SAVR than what had been previously thought [32]. 
Nevertheless, the incidence of a significant cogni-
tive impact seems to be similar between the two 
techniques [33]. Moreover, the higher stroke rate 
after SAVR before the matched analysis can also be 
explained by the relatively high use of mechanical 
prosthesis in the SAVR group (42.5%, 110 pa-
tients). The median age for the surgical group was 
69 ± 9.9 years old and the rate of previous atrial 
fibrillation was 17.5%. These two reasons, together 
with patients’ preference, had a crucial role in the 
decision of implanting a mechanical prosthesis but 
the potential risk of hemorrhagic stroke cannot 
be overlooked. Indeed, the impact on prognosis of 
mechanical prosthesis is an object of controversy, 
and this is the reason why these patients were 
excluded in the matched analysis. Several studies 
suggest a potential benefit compared with biologi-
cal prostheses across a broad range of age groups 
up to 70 years. Accordingly, the high use of this 
kind of prosthesis by surgeons in our institution 
(in agreement with alternative large series [34, 35] 
was performed mostly in patients below 70 years 
of age (n = 106, 96%) after a careful information 
concerning the risks of anticoagulation, valve 
thrombosis, and rate of re-intervention according 
to the selected valve. In general, our policy was to 
implant biological valves (surgical or TAVI) in all 
patients older than 75 years old.
What is more, the rate of new permanent 
pacemaker implantation did not present signifi-
cant differences between the matched groups, 
although it remained over 15% in the TAVI group. 
The clinical experience and the development of 
devices that can be more accurately deployed and 
potentially repositioned had clearly contributed to 
the decrease of the rate of permanent pacemaker 
implementation, far from the initial rate close to 
40% [36, 37].
In terms of valve hemodynamics, TAVI pa-
tients presented better aortic valve area and 
lower gradients. However, a higher degree of AR 
was detected. The high-rate of self-expandable 
prosthesis may partially explain both facts. The 
supravalvular position of the leaflets in this device 
has been related to better transvalvular gradients 
when compared to conventional surgery and to 
balloon-expandable prosthesis [37, 38]. What is 
more, the use of this prosthesis has been associated 
to higher rate of paravalvular leak, which indeed 
was related to higher mortality [39, 40]. The fact 
that patients were not matched according to ana-
tomical factors as the degree and distribution of 
calcium in the native valve may have conditioned 
our findings, but this limitation was present as well 
in main TAVI trials.
Follow-up outcomes
Although AR degree remained higher after 
TAVI, our experience with newer devices suggests 
similar results to that of surgical prosthesis (7% of 
moderate-severe AR according to recent research) 
[41]. Concerning the 1-year mortality rate, both 
global and cardiac mortality presented comparable 
results in the matched cohort irrespective of the 
therapeutic strategy. Concomitant cardiac disease 
had been excluded from the inclusion criteria of 
main trials [3, 4]. In the light of our results, the im-
pact of these factors in real-world practice seems to 
be acceptable, but further investigation is needed.
Limitations of the study
The main limitation of this study was its ret-
rospective and non-randomized nature that has 
been partially attenuated by the matching process. 
Moreover, the predominant use of self-expandable 
percutaneous valves may have conditioned the 
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results limiting its external validity for balloon-
expandable systems. Finally, the threshold used for 
selecting lower risk patients (logistic EuroSCORE 
< 20%) was in accordance with PARTNER trial, 
however, a stricter criterion may better reflect the 
group of lower risk patients. This fact could affect 
the sample size and power, thus it was discarded 
from the analysis.
Conclusions
In conclusion, TAVI is feasible and shows 
comparable results to surgery in terms of early, 
1-year mortality, as well as cerebrovascular events 
in patients with severe AS and intermediate to low 
operative risk. Better transvalvular gradients, yet 
higher rates of AR were found, however, newer 
devices showed comparable rates of AR. This is a 
heterogeneous group of patients requiring a more 
accurate assessment of surgical risk in order to 
improve validity of future research and improve 
their outcomes.
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